Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Analyst consensus and Net cash floor.
ACCE opinionAmerican Well Corporation Class A Common Stock (AMWL)
Fair value
Not available
ACCE price target
$11.50
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $13.57 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Net cash floor.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
42
out of 100
Analysts
14% buy
7 covering
P/E
0.0x
forward 0.0x
1-year return
+146.3%
Dividend yield
0.00%
American Well Corporation Class A Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
American Well sells Amwell, a telehealth platform that health systems and payers use to run virtual visits, along with its Amwell Psychiatric Care and Converge offerings for managed care members. The main structural appeal is the gross margin of 52.6%, which shows the software and service mix can earn a reasonable unit economic spread if the company can scale revenue faster than its fixed costs. Revenue is shrinking, though, down 26.6% on the latest reported year, and the operating margin of -19.6% and ROE of -29.1% show the business is still losing money at current volumes. Market cap is around $211M with no forward earnings to anchor a multiple, so the case rests entirely on whether the cost base can be cut fast enough to reach breakeven before cash runs low. That is a turnaround question, and it deserves a deeper look at the balance sheet and cash burn before anyone considers it further.